Cargando…

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: As immunotherapy is one of the leading treatment approaches in non-small cell lung cancer, immunotherapy primary or secondary resistance mechanism need to be deeply understood. Moreover, it is important to know how to avoid or overcome resistance – both have been widely discussed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalinka, Ewa, Wojas-Krawczyk, Kamila, Krawczyk, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341137/ https://www.ncbi.nlm.nih.gov/pubmed/37444609 http://dx.doi.org/10.3390/cancers15133499

Ejemplares similares

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Viral Infection and Lung Cancer Immunotherapy
por: Kalinka, Ewa, et al.
Publicado: (2021)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
por: Błach, Justyna, et al.
Publicado: (2021)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Aptamers in Non-Small Cell Lung Cancer Treatment
por: Wieleba, Irena, et al.
Publicado: (2020)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures
por: Wieleba, Irena, et al.
Publicado: (2022)

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients
por: Krawczyk, Paweł, et al.
Publicado: (2007)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
por: Krawczyk, Paweł, et al.
Publicado: (2022)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
por: Powrózek, Tomasz, et al.
Publicado: (2014)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
por: Kucharczyk, Tomasz, et al.
Publicado: (2022)

In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka
por: Strzemski, Maciej, et al.
Publicado: (2017)

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases
por: Kubiatowski, Tomasz, et al.
Publicado: (2020)

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report
por: Kamila, Wojas-Krawczyk, et al.
Publicado: (2013)

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8g8u1adifgpe84utav2t189gfe